Through the production of recombinant antibodies, scientists from the National Polytechnic Institute (IPN) in Mexico reported that they are working on the development of a more efficient vaccine against Human Papilloma virus (HPV). The specialists seek to contribute with a new alternative that prevents more women from dying from cervical cancer, the institute said in a statement.

Currently there are two vaccines that are marketed in the world to combat this disease and are effective when they are administered before a person has sexual activity, so it is vital to have new options against this disease.

Juan Sebastián Herrera Noreña, of the Interdisciplinary Professional Unit of Biotechnology (UPIBI), explained that the purpose of the research is to generate a new vaccine for HPV, because the current ones use molecules called adjuvants that cause secondary alterations.

Recombinant antibody therapy recognizes the pathogen or virus and binds to it, and a cascade of reactions begins so that the body generates a memory, like conventional vaccines do. The advantage is that it uses molecules produced by our own system,” Herrera Noreña said.

The development of this vaccine, produced in the UPIBI’s Molecular Biotechnology Laboratory, would represent the beginning of the eradication of cervical cancer worldwide and a drastic reduction of some types of cancer.

The specialist said that they use antibodies in mammalian cells of a cellular model called CHO (Chinese Hamster Ovary), which is responsible for producing the antibody. Having a human molecular origin, the antibody does not produce an unfavorable reaction in the human body.

The purpose of using recombinant antibodies is to choose a mark that has been conserved in all families and to fight all versions of HPV. There is an acceptable success rate between 60 and 70 percent; the idea of generating these vaccines is to improve their performance.

The polytechnic researcher said that the use of recombinant antibodies has the ability to neutralize almost any pathogen (viruses, fungi or bacteria). Likewise, they can stop the growth of any abnormal cell in the body.

We do not work directly with HPV, but with the proteins that produce it. These can be achieved or produced in vitro and are not pathogenic. They are proteins that we can easily work with and validate them. In the future, when we want to validate the antibody, it will be with mice or rabbits,” said Herrera Noreña.


Source: Agencia ID